KAT6B Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the KAT6B gene in the HAP1 human cell line. This product provides a loss-of-function model generated by CRISPR/Cas9-mediated gene disruption, without selection of individual clones. The polyclonal format maintains genetic heterogeneity while ensuring broad representation of editing events, enabling robust functional studies.
The HAP1 cell line is a near-haploid human fibroblast-like cell line derived from the KBM-7 chronic myeloid leukemia line. It grows adherently and is widely used in functional genomics due to its haploid karyotype, which facilitates straightforward gene knockout and minimizes compensation from a second allele. HAP1 cells provide a consistent background for high-throughput screening and detailed mechanistic assays.
KAT6B is a histone acetyltransferase and the catalytic subunit of the MOZ/MORF complex, which also includes ING5, BRPF1?C3, EPC1/2, and MEAF6. It acetylates lysine residues on histones H3 and H4, promoting chromatin relaxation and transcriptional activation. KAT6B acts as a coactivator for transcription factors RUNX1 and p53 and is regulated by Notch and Wnt signaling. Its downstream targets include HOXA genes and CDKN1A (p21), linking it to developmental processes, hematopoiesis, and tumor suppression.
In the HAP1 background, KAT6B knockout offers a clean system to dissect its contributions to chromatin remodeling and signaling. The leukemia-derived HAP1 line is particularly relevant for studying KAT6B’s role in acute myeloid leukemia and hematopoietic stem cell maintenance. The haploid state ensures that gene disruption yields unambiguous loss-of-function phenotypes, enabling precise analysis of p53 and Notch pathway activities.
Typical applications include western blotting and RT-qPCR for knockout validation, histone acetylation western blotting, ChIP-qPCR for acetylated histones, RNA-seq, and cell-based assays for proliferation and apoptosis. These cells are suitable for functional genomics, chromatin biology, developmental research, and drug target validation. For additional details, please contact Ascent Research.
